Providing products and solutions to the global healthcare market, can be a lucrative business, but it also requires continual innovation and speed to keep up with rapidly changing medical needs. The other challenge is trying to create change in an established market. ITL Health Group (ITL) is a Canberra based company that launched in 1994 and today holds 40 product patents and sells products to 55 countries throughout North and South America, Europe, Asia, the Middle East and Australia. ITL supplies products directly to health providers or works with strategic partners around the world to provide products and solutions to healthcare markets and to empower individuals to manage their own health.
Read the article in Canberra Business News.
The shareholders have voted overwhelmingly to remove ITL Health Group Limited from the official list of the ASX at the Extraordinary General Meeting held today at 10:00 am.
Read More “Company to delist from the ASX last trading day 8th February 2019” »
ITL Health Group Limited (‘ITL’) has today, following a resolution of the Board of Directors, submitted a formal application for the removal of ITL’s fully paid ordinary shares (‘Shares’) from the Official List of Australian Securities Exchange (‘ASX’) pursuant to ASX Listing Rule 17.11.
Read More “Voluntary Delisting from ASX—ITL Health Group Limited (ASX:ITD)” »
ITL Health Group (ASX:ITD), a manufacturer and seller of medical technology to the global blood industry and developer of innovative direct-to-consumer pathology testing services, announces results for the year ended 30 June 2018.
Read More “ITL Health Group Announces 2017/18 Results” »
ITL Health Group (ASX:ITD) was featured on Biotech Daily, a website which provides daily news on ASX-listed biotechnology companies.
Friday, 29th June 2018
Dr Boreham’s Crucible: ITL Health
Read article → Biotech Daily ITL Health Group Jun 29 2018
ITL Health Group (ASX:ITD) is pleased to announce the launch of ITL BioMedical’s latest innovative product to support the microbiology laboratory blood culture testing process. The Safety SubCulture Units 2 (SCU2) is one of a pipeline of new products to be brought to market in the current financial year.
Read More “ITL BioMedical Launches Safety SubCulture Unit 2” »
ITL Health Group (ASX:ITD) is pleased to announce the launch of ITL BioMedical’s latest pre-analytical products for blood culture sample collection, SampLok® Adapter Cap 2 and SampLok® Adapter Cap 3.
Read More “ITL BioMedical Launches More New Blood Sector Products” »
